Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MannKind Corporation - Common Stock (NQ:MNKD)

5.915 +0.325 (+5.81%)
Streaming Delayed Price Updated: 11:38 AM EST, Jan 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MannKind Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
MannKind to Present at Upcoming Investor Conferences
From MannKind
Via GlobeNewswire
MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together ↗
Via Stocktwits
News headline image
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
Initial collaboration led to Tyvaso DPI®, the first FDA-approved dry powder inhalation treatment for pulmonary hypertension 
From MannKind
Via GlobeNewswire
MannKind Announces $500M Financing Agreement With Blackstone After Q2 Revenue Miss: Retail Believes Stock Is ‘Ridiculously Undervalued’ ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
A Look Ahead: MannKind's Earnings Forecast ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
MannKind's Earnings Outlook ↗
 
Via Benzinga
News headline image
MannKind’s $360M scPharma Deal Splits Analysts — Retail Traders Call It ‘Bizarro Territory’ But Stay Bullish ↗
The deal hands MannKind access to scPharma’s Furoscix heart and kidney therapy, a product with a U.S. market potential estimated at over $10 billion. 
Via Stocktwits
News headline image
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal ↗
MannKind will acquire scPharmaceuticals in a $360 million deal, adding Furoscix and expanding into cardiometabolic care with a $10 billion U.S. market opportunity. 
Via Benzinga
News headline image
MannKind Corporation to Acquire scPharmaceuticals: More Details Inside ↗
The transaction is expected to close in the fourth quarter of 2025, subject to necessary approvals. 
Via Stocktwits
News headline image
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
From MannKind
Via GlobeNewswire
News headline image
Earnings Scheduled For February 26, 2025 ↗
 
Via Benzinga
News headline image
MannKind (MNKD) Q2 Revenue Rises 6% ↗
Via The Motley Fool
Topics Intellectual Property World Trade
News headline image
MannKind Corp (NASDAQ:MNKD) Q2 2025 Earnings Miss Estimates, Shares Drop 3.8% in Pre-Market ↗
MannKind Corp (MNKD) missed Q2 2025 revenue and EPS estimates, causing a 3.8% pre-market drop. Despite the miss, strategic moves like Blackstone's $500M financing and product pipeline progress offer... 
Via Chartmill
Topics Earnings
News headline image
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
From MannKind
Via GlobeNewswire
News headline image
MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update
Conference call today at 9:00 am ET 
From MannKind
Via GlobeNewswire
News headline image
MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025
From MannKind
Via GlobeNewswire
News headline image
Top 3 Health Care Stocks That May Rocket Higher This Quarter ↗
 
Via Benzinga
News headline image
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23
From MannKind
Via GlobeNewswire
News headline image
MannKind to Present at Upcoming Investor Conferences
From MannKind
Via GlobeNewswire
News headline image
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
From MannKind
Via GlobeNewswire
News headline image
MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025
From MannKind
Via GlobeNewswire
News headline image
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options
From MannKind
Via GlobeNewswire
News headline image
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
From MannKind
Via GlobeNewswire
News headline image
MannKind Stock Surges After-Hours On Q4 Revenue Beat, Debt Reduction As Retail Investors Celebrate ‘Amazing Comeback’ ↗
The company significantly reduced its debt principal by $236 million, leaving just $36 million in remaining convertible debt, and ended 2024 with $203 million in cash, cash equivalents, and... 
Via Stocktwits
News headline image
MannKind (MNKD) Q4 2024 Earnings Call Transcript ↗
MNKD earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Conference call to provide corporate updates today at 4:30 pm ET 
From MannKind
Via GlobeNewswire
News headline image
MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025
From MannKind
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.